Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa

American Journal of Health-System Pharmacy

Volumn 62, Issue 23, 2005, Pages 2524-2526

  Norgard, Nick ^a   Wall, Geoffrey C ^b,c  

^a IOWA METHODIST MEDICAL CENTER   (United States)

^b IMMC   (United States)

^c DRAKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; FERROUS SULFATE; FUROSEMIDE; IMIPENEM; MINOXIDIL; RECOMBINANT ERYTHROPOIETIN; VANCOMYCIN;

ADULT; ANEMIA; BLOOD CELL COUNT; BLOOD CHEMISTRY; CASE REPORT; CHILL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG ERUPTION; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA MULTIFORME; FEVER; HEMODIALYSIS; HUMAN; HYPERTENSION; MALAISE; MALE; PRIORITY JOURNAL; PRURITUS; REVIEW; SINGLE DRUG DOSE; SKIN BIOPSY;

EID: 28344437507     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050175     Document Type: Review

References (16)

1. Procrit (epoetin alfa) prescribing information. Raritan, NJ: Ortho-Biotech, Inc.; 2005 Jan.
2. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
3. Bright RA, Torrence ME, Daley WR et al. Preliminary survey of the occurrence of anaphylactoid reactions during haemodialysis. Nephrol Dial Transplant. 1999; 14:799-800. Letter.
4. Immune responses in the absence of infection. In: Janeway CA Jr, Travers P, eds. Immunobiology: the immune system in health and disease. 2nd ed. London: Garland; 1995.
5. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19:2875-82.
6. Allam JP, Paus T, Reichel C et al. DRESS syndrome associated with carbamazepine and phenytoin. Eur J Dermatol. 2004; 14:339-42.
7. Knudtson E, Para M, Boswell H et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003; 101:1094-7.
8. Bagshaw SM, Cload B, Gilmour J et al. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol. 2003; 90:572-5.
9. Bachot N, Roujeau JC. Physiopathology and treatment of severe drug reactions. Curr Opin Allergy Clin Immunol. 2001; 1:293-8.
10. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003; 4:561-72.
11. Huff JC. Erythema multiforme. In: Sams WM, Lynch PJ, eds. Principles and practice of dermatology. 2nd ed. New York: Churchill-Livingstone; 1996:483-96.
12. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004; 24:477-90.
13. Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004; 15:2728-34.
14. Weber G, Gross J, Kromminga A et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002; 13:2381-3.
15. Wolf IH, Smolle J, Cerroni L et al. Erythroderma with lichenoid granulomatous features induced by erythropoietin. J Cutan Pathol. 2005; 32:371-4.
16. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002; 8:5.